Slow-release carvedilol was associated with a significantly lower risk of major adverse cardiovascular events compared to immediate-release carvedilol (HR 0.61; 95% CI 0.556-0.670; p<0.001).
Cohort (n=38,563)
Yes
Does slow-release carvedilol reduce major adverse cardiovascular events compared to immediate-release carvedilol in patients requiring beta-blocker therapy?
In a large real-world cohort, slow-release carvedilol was associated with a significantly lower risk of MACE compared to immediate-release carvedilol, though randomized trials are needed to confirm causality.
Effect estimate: HR 0.61 (95% CI 0.556-0.670)
p-value: p=<0.001
Background: Carvedilol, a non-selective β- and α1-blocker, is available in immediate-release (IR) and slow-release (SR) formulations. While carvedilol IR requires twice-daily dosing, SR was developed to improve adherence by allowing once-daily administration. This study aimed to compare long-term clinical outcomes between SR and IR carvedilol. Methods: A total of 38,563 patients taking either SR (n = 6223) or IR carvedilol (n = 32,340) were retrospectively analyzed using national claims data. Baseline characteristics, medication adherence, and cardiovascular outcomes were evaluated over a median follow-up period of 730 days. Multivariable Cox regression analyses were performed to adjust for potential confounders. Results: Despite a higher burden of comorbidities in the SR group, patients taking SR carvedilol had significantly lower risks of major adverse cardiovascular events (MACE), non-fatal myocardial infarction, and heart failure hospitalization compared to those on IR carvedilol. The adjusted hazard ratio for MACE with SR compared to IR was 0.61 (95% CI, 0.556–0.670; p < 0.001). No significant difference in non-fatal stroke was observed between the groups. Conclusions: In this claims-based observational cohort, SR carvedilol was associated with more favorable long-term cardiovascular outcomes than IR carvedilol. However, this association does not establish causal superiority, and prospective randomized studies are needed to confirm these findings.
Kim et al. (Wed,) reported a cohort. Slow-release (SR) carvedilol vs. Immediate-release (IR) carvedilol was evaluated on major adverse cardiovascular events (MACE) (HR 0.61, 95% CI 0.556-0.670, p=<0.001). Slow-release carvedilol was associated with a significantly lower risk of major adverse cardiovascular events compared to immediate-release carvedilol (HR 0.61; 95% CI 0.556-0.670; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: